The optimized results of the 118-Bus. by Ahmed A. Zaki Diab (12757190)

“…The efficacy of the utilized techniques is validated through testing on two distinct networks, namely the IEEE 33 and 69 buses RDS in MATLAB, with attainments compared against other techniques. Moreover, a larger RDS system of 118- bus IEEE system has been considered in order to enhance its power quality indices. …”

Single line diagram of RDN. by Ahmed A. Zaki Diab (12757190)

“…The efficacy of the utilized techniques is validated through testing on two distinct networks, namely the IEEE 33 and 69 buses RDS in MATLAB, with attainments compared against other techniques. Moreover, a larger RDS system of 118- bus IEEE system has been considered in order to enhance its power quality indices. …”

Supporting information. by Ahmed A. Zaki Diab (12757190)

“…The efficacy of the utilized techniques is validated through testing on two distinct networks, namely the IEEE 33 and 69 buses RDS in MATLAB, with attainments compared against other techniques. Moreover, a larger RDS system of 118- bus IEEE system has been considered in order to enhance its power quality indices. …”

LSF for 118 Bus. by Ahmed A. Zaki Diab (12757190)

“…The efficacy of the utilized techniques is validated through testing on two distinct networks, namely the IEEE 33 and 69 buses RDS in MATLAB, with attainments compared against other techniques. Moreover, a larger RDS system of 118- bus IEEE system has been considered in order to enhance its power quality indices. …”

Effect of let-7a on expression of E2F2 and CCND2. by Qingchuan Dong (250327)

“…After transfected with let-7a, the expression levels of E2F2, CCND2, and k-ras decreased dramatically in PC3-let-7a-GFP cells compared with that in PC3-GFP cells. β-actin was used the loading control.…”

<i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significant... by Milo B. Fasken (659389)

“…<i>nab3-R331A</i>, <i>nab3-F333A</i>, and <i>nab3-S399A</i> RRM mutants do not decrease level of GFP from pREF-GFP reporter in <i>air1/2</i> cells. …”

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Several components contribute to detection of the mixture. by Majid Ghaninia (37312)

“…(A) In <i>Apis mellifera</i> omission of phenylacetaldehyde, nonanal, decanal, acetophenone, and p-anisaldehyde from the blend significantly decreased the responses elicited by the OSNs. …”

Spatial distribution of 12 class B notifiable infectious diseases in China: A retrospective study by Bin Zhu (182882)

“…<div><p>Background</p><p>China is the largest developing country with a relatively developed public health system. …”

Thymol and its combination with classical anthelmintics. by Guillermina Hernando (553795)